Impact of response to thalidomide-, lenalidomide- or bortezomib-containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

被引：5
|
作者：
Awan, F. T. [1 ]
Osman, S. [2 ]
Kochuparambil, S. T. [1 ]
Gibson, L. [2 ]
Remick, S. C. [2 ]
Abraham, J. [2 ]
Craig, M. [2 ]
Jillella, A. [1 ]
Hamadani, M. [2 ]
机构：
[1] Med Coll Georgia, Dept Internal Med, Div Hematol Oncol, Augusta, GA 30912 USA
[2] W Virginia Univ, MBRCC, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷 / 01期
关键词：
BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; AUTOTRANSPLANTATION; CHEMOTHERAPY; TRIAL;
D O I：
10.1038/bmt.2011.18
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：146 / 148
页数：3
相关论文
共 50 条
  • [21] Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Li, Zhiguo
    Sung, Anthony D.
    Sarantopoulos, Stefanie
    Kang, Yubin
    Long, Gwynn D.
    Horwitz, Mitchell E.
    Lopez, Richard D.
    Sullivan, Keith M.
    Rizzieri, David A.
    Chao, Nelson J.
    Gasparetto, Cristina
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (02) : 262 - 268
  • [22] Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation
    Malkan, U.
    Buyukasik, Y.
    Demiroglu, H.
    Ciftciler, R.
    Gunes, G.
    Okay, M.
    Aladag, E.
    Aksu, S.
    Sayinalp, N.
    Haznedaroglu, I.
    Ozcebe, O.
    Kelkitli, E.
    Turgut, M.
    Goker, H.
    LEUKEMIA RESEARCH, 2018, 73 : S55 - S56
  • [23] Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation
    Wen Gao
    Jie Li
    Yuan Jian
    Guangzong Yang
    Yin Wu
    Yanchen Li
    Yun Len
    Aijun Liu
    Ying Tian
    Huijuan Wang
    Huixing Zhou
    Zhiyao Zhang
    Wenming Chen
    International Journal of Hematology, 2019, 109 : 169 - 174
  • [24] Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
    Huang, Shang-Yi
    Lin, Chung-Wu
    Lin, Hsiu-Hsia
    Yao, Ming
    Tang, Jih-Luh
    Wu, Shang-Ju
    Chen, Yao-Chang
    Lu, Hsiao-Yun
    Hou, Hsin-An
    Chen, Chien-Yuan
    Chou, Wen-Chien
    Tsay, Woei
    Chou, Sheng-Je
    Tien, Hwei-Fang
    ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1371 - 1380
  • [25] Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Shah, Gunjan L.
    Seier, Kenneth
    Devlin, Sean M.
    Chung, David J.
    Scordo, Michael
    Hultcrantz, Malin
    Korde, Neha
    Lendvai, Nikoletta
    Lesokhin, Alexander M.
    Mailankody, Sham
    Smith, Eric L.
    Landgren, Ola
    Landau, Heather J.
    Giralt, Sergio
    BLOOD, 2018, 132
  • [26] Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
    Shang-Yi Huang
    Chung-Wu Lin
    Hsiu-Hsia Lin
    Ming Yao
    Jih-Luh Tang
    Shang-Ju Wu
    Yao-Chang Chen
    Hsiao-Yun Lu
    Hsin-An Hou
    Chien-Yuan Chen
    Wen-Chien Chou
    Woei Tsay
    Sheng-Je Chou
    Hwei-Fang Tien
    Annals of Hematology, 2014, 93 : 1371 - 1380
  • [27] Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation
    Gao, Wen
    Li, Jie
    Jian, Yuan
    Yang, Guangzong
    Wu, Yin
    Li, Yanchen
    Len, Yun
    Liu, Aijun
    Tian, Ying
    Wang, Huijuan
    Zhou, Huixing
    Zhang, Zhiyao
    Chen, Wenming
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (02) : 169 - 174
  • [28] Early versus delayed autologous stem cell transplantation in patients receiving bortezomib, thalidomide-based induction for multiple myeloma
    Tolhi, S.
    Osmani, S.
    Yafour, N.
    Mohamed, B.
    Arabi, A.
    Bouhass, R.
    Bekadja, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S213 - S213
  • [29] Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients With Symptomatic Multiple Myeloma A Retrospective Study
    Kaufman, Jonathan L.
    Nooka, Ajay
    Vrana, Mark
    Gleason, Charise
    Heffner, L. Thompson
    Lonial, Sagar
    CANCER, 2010, 116 (13) : 3143 - 3151
  • [30] Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
    Gay, Francesca
    Falco, Patrizia
    Crippa, Claudia
    Liberati, Marina
    Patriarca, Francesca
    Cangialosi, Clotilde
    Capparella, Vincenzo
    Siniscalchi, Agostina
    Rizzo, Manuela
    De Rosa, Luca
    Falcone, Antonietta Pia
    Caltagirone, Simona
    Bringhen, Sara
    Corradini, Paolo
    Boccadoro, Mario
    Palumbo, Antonio
    BLOOD, 2009, 114 (22) : 1328 - 1328
12345